Lutetium (177lu) lilotomab satetraxetan

Drug Profile

Lutetium (177lu) lilotomab satetraxetan

Alternative Names: 177Lu lilotomab satetraxetan; 177Lu-DOTA-HH1; 177Lu-Dota-tetulomab; 177Lu-tetraxetan-tetulomab; 177Lutetulomab; Betalutin; Lutetium 177Lu lilotomab satetraxetan

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nordic Nanovector
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD37 protein inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Follicular lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 01 Nov 2017 Additional efficacy data from the phase I/II LYMRIT 37-01 trial in Non-Hodgkin's lymphoma released by Nordic Nanovector
  • 23 Aug 2017 Nordic Nanovector anticipates the first regulatory submission for in relapsed/refractory follicular lymphoma in the first half of 2019
  • 14 Jun 2017 Topline adverse events and efficacy data from the phase I/II trial in Non hodgkin's lymphoma released by Nordic Nanovector
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top